Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | Milvexian - (AXIOMATIC-TKR) | Venous thromboembolism (VTE) prevention post total knee replacement (TKR) surgery | Phase 2 | Data Released | Oral | Anticoagulant |
| Bristol-Myers Squibb Company | BNT327-06 | First line NSCLC | Phase 2/3 | Enrollment Initiation | Intravenous | Oncology |
| Bristol-Myers Squibb Company | BMS-986504 (PRMT5 inhibitor) - (MountainTAP-30) | 1L Metastatic PDAC (with Homozygous MTAP deletion) | Phase 2/3 | Ongoing | oral | Oncology |
| Bristol-Myers Squibb Company | Camzyos (mavacamten) - (SCOUT-HCM) | Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) | Phase 3 | Data Released | Oral | Cardiology |
| Bristol-Myers Squibb Company | Nivolumab - (CheckMate 238) | Resected stage IIIB–C or IV melanoma | Phase 3 | Data Released | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Bempegaldesleukin (NKTR-214) and OPDIVO (nivolumab) - (PIVOT-10) | Urothelial cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Iza-bren (izalontamab brengitecan, EGFR x HER3 ADC) - (IZABRIGHT-Breast01) | 1L Triple Negative Breast Cancer (TNBC) | Phase 2/3 | Ongoing | Intravenous | Oncology |
| Bristol-Myers Squibb Company | REBLOZYL (Luspatercept) - (COMMANDS) | Non-transfusion-dependent beta-thalassemia | Phase 2 | Data Released | Subcutaneous injection | Genetic Disorder |
